ErlySign, the Nagpur-based biotech startup developing India’s first salivary biomarker–based screening test for early-stage ...

"Vaximm and BCME link on oral cancer immunotherapy platform" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization novel ...

ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older – -Oral pellet formulation provides ...

Eight oral presentations and six posters demonstrate advances in mammography, DBT performance, and density-informed risk modeling ...

ORLADEYO is now the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and above. A capsule ...

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as ...

Hutchmed announces expanded coverage on National Reimbursement Drug List and inclusion in the first Commercial Insurance Drug List in China: Hong Kong, Shanghai Tuesday, December ...

Presentation Title: The ADELA study: A Double-blind, Placebo-controlled, Randomized Phase 3 Trial of Elacestrant (ELA)+ Everolimus (EVE) Versus ELA + Placebo (PBO) in ER+/HER2-Advanced Breast Cancer ...

(9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class ...

Denmark-based clinical-stage techbio Evaxion Biotech, which is specializing in developing AI-Immunology powered vaccines, ...